Valence8 US LP Takes $282,000 Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Valence8 US LP acquired a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 2,468 shares of the company’s stock, valued at approximately $282,000.

A number of other hedge funds have also modified their holdings of the company. Darwin Global Management Ltd. increased its position in shares of Vaxcyte by 374.3% in the first quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock valued at $187,907,000 after acquiring an additional 2,170,845 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Vaxcyte by 15.2% during the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock worth $665,152,000 after purchasing an additional 1,284,883 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Vaxcyte by 9.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock valued at $524,117,000 after buying an additional 692,492 shares during the last quarter. Avoro Capital Advisors LLC acquired a new stake in shares of Vaxcyte in the 1st quarter valued at approximately $39,278,000. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Vaxcyte by 18.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock valued at $216,966,000 after buying an additional 498,359 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Stock Up 2.8 %

Shares of NASDAQ:PCVX opened at $88.39 on Friday. The stock has a market cap of $11.02 billion, a PE ratio of -19.22 and a beta of 1.01. Vaxcyte, Inc. has a 12-month low of $48.24 and a 12-month high of $121.06. The business has a 50 day moving average of $108.44 and a 200-day moving average of $89.10.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter in the prior year, the firm earned ($0.91) EPS. Equities research analysts expect that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total transaction of $927,520.00. Following the completion of the transaction, the chief financial officer now directly owns 90,383 shares in the company, valued at $10,479,005.02. The trade was a 8.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Grant Pickering sold 7,098 shares of the firm’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $109.21, for a total value of $775,172.58. Following the completion of the sale, the chief executive officer now directly owns 138,581 shares in the company, valued at approximately $15,134,431.01. This represents a 4.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 102,464 shares of company stock valued at $11,455,576 in the last three months. Corporate insiders own 3.10% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Needham & Company LLC reiterated a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research note on Wednesday, November 6th. Bank of America boosted their price target on Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Leerink Partners raised their price objective on Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research report on Tuesday, September 3rd. Finally, BTIG Research boosted their target price on Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte presently has an average rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.